Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study

Autor: Yaron Arbel, MD, Ashish D. Patel, MD, Shaun G. Goodman, MD, MSc, Mary K. Tan, MSc, Neville Suskin, MBChB, MSc, Robert S. McKelvie, MD, PhD, Andrew L. Mathew, MD, Firas Ahmed, MD, Sohrab Lutchmedial, MDCM, Payam Dehghani, MD, Andrea J. Lavoie, MD, Thao Huynh, MD, MSc, PhD, Shahar Lavi, MD, Razi Khan, MD, Andrew T. Yan, MD, Christopher B. Fordyce, MD, MHS, MSc, Michael Heffernan, MD, PhD, Sean Jedrzkiewicz, MD, Mina Madan, MD, MHS, Shaheeda Ahmed, MD, Colin Barry, MD, Jean-Pierre Dery, MD, Akshay Bagai, MD, MHS

Publikováno v: CJC Open, Vol 3, Iss 12, Pp 1463-1470 (2021)

Background: Extension of dual antiplatelet therapy (DAPT) beyond 1 year after acute coronary syndrome is associated with a reduction in ischemic events but also increased bleeding. The DAPT score identifies individuals likely to derive overall benefi

Externí odkaz: https://doaj.org/article/fd68407c74874c37becfa032cd240cd6

Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada

Autor: Ashlay A. Huitema, MD, FRCPC, Alexia Daoust, MSc, Kim Anderson, MD, MSc, FRCPC, Stephanie Poon, MD, MSc, FRCPC, Sean Virani, MD, MSc, MPH, FRCPC, FCCS, Michel White, MD, FRCP(C), FACC, FESC, Carlos Rojas-Fernandez, PharmD, Shelley Zieroth, MD, FCCS, FRCPC, Robert S. McKelvie, MD, PhD, FRCPC

Publikováno v: CJC Open, Vol 2, Iss 5, Pp 321-327 (2020)

Background: Heart failure (HF) with reduced ejection fraction represents approximately 50% of the 600,000 Canadians currently living with HF and over 90,000 new cases diagnosed each year. The angiotensin receptor neprilysin inhibitor, sacubitril/vals

Externí odkaz: https://doaj.org/article/4bb07964bbbc49ec83744e7c69521979

Prévention et traitement de l’hyperkaliémie chez les patients sous inhibiteurs du système rénine–angiotensine–aldostérone

Autor: Jordan Weinstein, Louis-Philippe Girard, Serge Lepage, Robert S. McKelvie, Karthik Tennankore

Publikováno v: Canadian Medical Association Journal. 194:E391-E397

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a65f2fc033371648973e356235b0b265
https://doi.org/10.1503/cmaj.210831-f

Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study

Autor: Jean-Pierre Déry, Yaron Arbel, Payam Dehghani, Ashish Patel, Christopher B. Fordyce, Mina Madan, Shahar Lavi, Colin Barry, Sean Jedrzkiewicz, Robert S. McKelvie, Andrew L. Mathew, Michael Heffernan, Mary K. Tan, Andrea Lavoie, Razi Kahn, Firas Ahmed, Thao Huynh, Neville Suskin, Shaheeda Ahmed, Akshay Bagai, Sohrab Lutchmedial, Andrew T. Yan, Shaun G. Goodman

Publikováno v: CJC Open
CJC Open, Vol 3, Iss 12, Pp 1463-1470 (2021)

Background: Extension of dual antiplatelet therapy (DAPT) beyond 1 year after acute coronary syndrome is associated with a reduction in ischemic events but also increased bleeding. The DAPT score identifies individuals likely to derive overall benefi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03f4d4d8d24343ca374210a4cfb14859
http://europepmc.org/articles/PMC8712544

Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction

Autor: Michel Komajda, Lars Køber, Pardeep S. Jhund, Robert S. McKelvie, Akshay S. Desai, John J.V. McMurray, Inder S. Anand, Li Shen, Peter E. Carson, Karl Swedberg, Michael R. Zile, Christopher B. Granger, Scott D. Solomon, Marc A. Pfeffer

Publikováno v: Clinical Research in Cardiology
Shen, L, Jhund, P S, Anand, I S, Carson, P E, Desai, A S, Granger, C B, Køber, L, Komajda, M, McKelvie, R S, Pfeffer, M A, Solomon, S D, Swedberg, K, Zile, M R & McMurray, J J V 2021, ' Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction ', Clinical Research in Cardiology, vol. 110, no. 8, pp. 1234-1248 . https://doi.org/10.1007/s00392-020-01786-8

Background Sudden death (SD) and pump failure death (PFD) are leading modes of death in heart failure and preserved ejection fraction (HFpEF). Risk stratification for mode-specific death may aid in patient enrichment for new device trials in HFpEF. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11a19ee9a84f4d8466f7798e52411605
https://doi.org/10.1007/s00392-020-01786-8